A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2017
At a glance
- Drugs CVA 21 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Viralytics
- 20 Sep 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 06 Jul 2016 Status changed from planning to not yet recruiting.